Morning Brief — September 18, 2026

Market Overview

The Fed delivered a 25bps rate hike to 3.75–4.00% yesterday and signaled more tightening ahead, yet futures are green this morning as strong August retail sales (+1.2%) and a “resilience hope” narrative dominate the tape. Tech is leading the recovery — Nasdaq futures up ~1%, S&P futures up ~0.8% — with AI infrastructure names and biotech both catching bids. The macro backdrop remains a tug-of-war: rate hikes argue for caution, but the market’s refusal to sell off post-hike is itself a bullish signal.

Claude’s Call

UP — The market’s ability to shrug off a hawkish Fed hike and close higher yesterday demonstrated genuine buying conviction, and with retail sales surprising to the upside, the path of least resistance is higher today. The AI infrastructure rally (SMCI, AMD, NVDA-adjacent names) has real momentum behind it, and I expect the S&P 500 to build on yesterday’s gains through the session.

Top Movers

SDGR (+26.4%) — $30.24 → $35.45 (+17.2% upside) Thesis: Schrödinger is surfing the AI drug discovery wave — it’s up 26% today and 61% on the week after a prior session surge, with the catalyst being continued positive earnings estimate revision momentum in computational drug discovery. This isn’t a one-day fluke; the AI pharma theme has legs as Zacks and multiple outlets highlight RXRX/SDGR/ABSI as a cohort. Technically, SDGR just hit its 6-month high at $30.24, breaking decisively above the 50-day SMA ($18.44) and nearly tripling off the 6-month low of $11.07. The next fib extension target is $35.45 (1.272 ext). Levels: Exit at $35.45 (Fib 1.272 extension). Support at $25.72 (Fib 23.6% retracement) — a pullback there is the first real test. Caution: vol_vs_avg is only 0.24 — that’s low volume on a massive move, which is a yellow flag for sustainability.

VICR (+17.7%) — $216.39 → $261.00 (+20.6% upside) Thesis: Real, company-specific catalyst here — Vicor announced a new non-exclusive licensing agreement for its Vertical Power Delivery (VPD) technology to an unnamed OEM building AI/networking processors. This is directly in the path of AI infrastructure capex, and licensing deals are high-margin, recurring revenue. Noteworthy that it’s made Zacks’ “green stocks crushing clean energy ETFs” list for 2026. Technically, VICR is at $217.90 — well below its 6-month high of $379.78, meaning it has significant room to recover. The 50 SMA ($211.42) is just below, offering near-term support. The Fib 61.8% retracement of the 6-month range sits at $232.97, which is the first meaningful resistance to clear. Levels: Exit at $261.00 (Fib 50% retracement of 6-month range acts as resistance). Support at $211.42 (50-day SMA). Note: vol_vs_avg at 0.08 is very thin — confirms this is a low-float, catalyst-driven pop. Be careful with sizing.

TEM (+14.9%) — $80.36 → $90.92 (+13.1% upside) Thesis: Tempus AI is up 37% on the week on a genuine fundamental re-rating — Morgan Stanley reframed the Medicare reimbursement revenue story for two cancer screenings, and the market is scrambling to reprice. This isn’t sector sympathy; it’s a coverage-driven catalyst with institutional credibility. That said, RSI is only 35.54, which is surprising for a 37% weekly gainer — suggests the prior base was deeply oversold. Technically, TEM just hit its 6-month high at $80.36, having rallied from $41.55 (6mo low). The Fib 1.272 extension is $90.92 — that’s the near-term target. Levels: Exit at $90.92 (Fib 1.272 extension). Support at $71.20 (Fib 23.6% retracement) — a healthy pullback level for re-entry on weakness.

TWST (+8.7%) — $155.56 → $190.21 (+22.3% upside) Thesis: Twist Bioscience hit a multi-year high on a real deal catalyst — a collaboration with Lilly TuneLab to provide antibody characterization data for Lilly’s AI/ML drug discovery models. This is a direct picks-and-shovels play on AI drug discovery, plugging Twist’s DNA synthesis capabilities into one of the world’s largest pharma R&D ecosystems. Yes, Martin Shkreli called it a short — but his track record as a contrarian signal is notably poor. The stock is at its 6-month high ($158.53), and the 50-day SMA is way back at $118.14, showing the move has been sustained over weeks. Levels: Exit at $190.21 (Fib 1.272 extension). Support at $131.05 (Fib 23.6% retracement). This is already extended off its base — tighten stops if it can’t hold above $145 on any pullback.

SMCI (+9.5%) — $40.35 → $50.17 (+24.3% upside) Thesis: Super Micro Computer is riding the $1.3 trillion AI server boom narrative with no single bombshell catalyst today — this is sector momentum as Dell’s AI backlog data and broader AI infrastructure optimism lift the group. SMCI was already recovering from its 6-month low of $20.53 and has nearly doubled. The 50-day SMA ($33.57) is well below current price, suggesting trend is intact. Technically, SMCI is bumping against the 6-month high of $50.17 — that’s the key breakout level to watch. Current price at $40.35 is below the Fib 23.6% retracement of $43.17, which is near-term resistance. Levels: Exit at $50.17 (6-month high / prior resistance). Support at $38.85 (Fib 38.2% retracement). Sector sympathy is the weaker part of this thesis — needs volume confirmation to trust the breakout.

CRSP (+9.8%) — $57.33 → $66.66 (+16.3% upside) Thesis: CRISPR Therapeutics is bouncing as the gene-editing sector breaks out of a cup-with-handle base (per IBD-style technicals cited in the news). CASGEVY uptake momentum is building, and the stock had been underperforming — down 15% YoY before today’s move. The fundamental setup is real: a commercial product on market (CASGEVY), pipeline expansion, and sector rotation into biotech. Technically, current price ($58.15) is right at the Fib 23.6% retracement support level of $57.75 — that’s actually a nice setup where the stock is bouncing off support, not extended. Levels: Exit at $66.66 (Fib 1.272 extension). Support at $55.19 (Fib 38.2%) / $53.06 (50-day SMA). Clean technical setup with room to run — one of the better risk/reward charts in today’s mover list.

CMPS (+8.7%) — $15.00 → $17.88 (+19.2% upside) Thesis: Compass Pathways has been building toward this — 52-week Phase 3 data showed sustained depression relief with COMP360 psilocybin therapy, with patients gaining an average 13-point improvement in depression scores. A 2027 launch timeline is on the table. The RSI at 12.56 is screaming oversold — this is one of the most oversold names on today’s mover list, and the bounce from deeply depressed levels on clinical data is a legitimate catalyst. At $15, it’s approaching its 6-month high of $15.17, and a breakout above that is the key confirmation. Levels: Exit at $17.88 (Fib 1.272 extension). Support at $13.23 (50-day SMA / 20-day low). The “fully priced” concern from analysts is real — this is a binary biotech play, not a safe swing trade.

Headlines to Watch

Fed hikes 25bps to 3.75–4.00%, signals more tightening ahead — A rate hike cycle restart means growth stocks face a higher discount rate headwind; any guidance that assumes easy money is now stale, and rate-sensitive sectors (utilities, REITs, long-duration biotech) face renewed pressure.
Tempus AI surges on Morgan Stanley Medicare reimbursement re-rating — This is a template for how AI healthcare names get re-priced when revenue visibility improves; watch for similar analyst re-ratings on CRSP, CAI, and other precision medicine names as reimbursement clarity emerges.
Vicor licenses Vertical Power Delivery to unnamed AI OEM — The AI power delivery infrastructure theme is widening beyond GPU makers; VICR, Bloom Energy, and similar “power for AI” plays could see sustained institutional interest as the data center buildout accelerates.
Twist Bioscience + Lilly TuneLab AI drug discovery collaboration — Lilly is now plugging external DNA/antibody platforms into its AI drug discovery stack; this validates the picks-and-shovels thesis for TWST, SDGR, and ABSI as infrastructure plays rather than drug risk plays.
CLARITY Act collapses in Senate; Ethereum rallies anyway — Crypto regulatory clarity remains elusive, but PURR and crypto-adjacent treasury stocks (Bitmine, Sharplink) are rallying regardless; this suggests the market is pricing in eventual regulatory passage, but Senate failure is a real overhang.
Netflix cut to Underweight at Wells Fargo with $57 target — With competing analyst targets nearly double that level, this is a conviction dispersion moment; the streaming wars narrative may be shifting from growth to margin concern — watch Disney (DIS) and streaming ETFs for follow-through.
August retail sales +1.2% surprises to the upside — Strong consumer spending data gives the Fed cover for further hikes but also signals economic resilience; this is a mild tailwind for consumer discretionary and a validation that the economy can absorb the current tightening cycle.

Claude’s Top Picks

CRSP (+9.8% today, +9.7% week) — $57.33 → $66.66 (+16.3% upside) Valuation: No comps provided, but as a commercial-stage gene editing company with CASGEVY on market, CRSP is valued more like late-stage biotech than pre-revenue — the asset base justifies a premium to burn-rate names. Upside: Bouncing off the Fib 23.6% support at $57.75 with a clean technical setup, sector breakout tailwind from gene-editing peers, and CASGEVY commercial uptake providing a fundamental anchor the others in this group lack. Risk: If CASGEVY adoption data disappoints in the next update, or if the broader biotech rotation reverses on continued Fed hawkishness, CRSP could give back half this move quickly — stop below $53.06 (50-day SMA).

TWST (+8.7% today, +22.6% week) — $155.56 → $190.21 (+22.3% upside) Valuation: Trading at a multi-year high with no comps provided, but the Lilly collaboration de-risks the revenue story and transitions TWST from “DNA synthesis commodity” to “AI drug discovery infrastructure” — a meaningful multiple re-rating catalyst. Upside: The Lilly TuneLab deal is a real, named, high-profile partnership that embeds Twist into Lilly’s AI discovery pipeline with purchase commitments — this creates durable, visible revenue rather than one-time upside. Risk: Martin Shkreli’s short thesis (even if often wrong) highlights that the stock has run 277% off its 6-month low — any deal execution concern or broader biotech risk-off could see a violent 20–30% correction from current levels; stop below $131 (Fib 23.6%).

TEM (+14.9% today, +36.8% week) — $80.36 → $90.92 (+13.1% upside) Valuation: No comps provided, but the Morgan Stanley reimbursement re-rating is a fundamental upgrade to the revenue model — Medicare reimbursement for two cancer screenings is recurring, visible revenue that changes the valuation framework entirely. Upside: RSI at only 35.54 despite a 37% weekly gain suggests the prior base was deeply depressed and there’s more room for normalization; institutional investors following the Morgan Stanley upgrade are still building positions. Risk: At the 6-month high with no near-term technical resistance to guide price discovery, momentum names like TEM can reverse as fast as they run — the week-long 37% surge means any negative data point on reimbursement rates or guidance could spark a 20%+ reversal.

SMCI (+9.5% today, +8.0% week) — $40.35 → $50.17 (+24.3% upside) Valuation: No specific comps provided, but SMCI trades at a discount to pure-play AI infrastructure names given its accounting/governance history — that discount is narrowing as AI server demand overrides reputational concerns. Upside: The $1.3 trillion AI server market narrative is gaining institutional traction, and SMCI has the clearest direct exposure among publicly traded AI server manufacturers at a price still 20% below its 6-month high. Risk: This is sector momentum, not a company-specific catalyst today — if AI infrastructure sentiment shifts (e.g., hyperscaler capex cut announcements, NVDA guidance miss), SMCI will be the first to drop; support at $38.85 (Fib 38.2%), stop below $35.17 (20-day low).

VICR (+17.7% today, +21.5% week) — $216.39 → $261.00 (+20.6% upside) Valuation: Still 43% below its 6-month high of $379.78 despite today’s surge — the VPD licensing model is high-margin and recurring, and the market has not yet re-rated VICR to reflect the AI power delivery opportunity. Upside: The VPD licensing deal is company-specific, high-margin, and directly in the path of AI infrastructure buildout — this is the kind of “picks and shovels” play (power delivery for AI chips) that gets sustained institutional interest, not just a one-day pop. Risk: Volume is extremely thin (vol_vs_avg: 0.08) — this move was made on low liquidity, which means it can reverse just as quickly; the 50-day SMA at $211.42 is the critical floor, and a break below that would signal the pop is fading.

Avoid

SDGR — Up 61% in a week on earnings estimate revisions and sector sympathy (no company-specific hard catalyst), trading at its 6-month high on volume that’s only 24% of average — this has all the hallmarks of a low-liquidity pump that reverses before new buyers can exit.

PURR — A crypto treasury proxy (HYPE holdings) at its all-time high with the CLARITY Act just collapsing in the Senate; the 100% analyst upside targets and Trump White House narrative are the exact conditions where retail momentum peaks and smart money exits.

ABSI — “Baldness drug stock” narrative with -46% revenue growth, a negative forward P/E of -14x, and no hard clinical catalyst today — this is riding sector sympathy from the hair-loss biotech theme and the broader AI drug discovery wave; with revenue contracting sharply, the valuation “cheap” flag is misleading for a pre-revenue drug developer.

WSB Sentiment Check

MU — WSB says: MIXED (55% bullish) Claude says: PARTIALLY AGREE — MU at $988 is between its 50-day SMA ($926) and the 6-month high ($1,213); it’s in no man’s land technically, and with the Fed hiking, the memory cycle timing matters more than sentiment — wait for a clearer entry below $930 or a confirmed break above $1,000.

NBIS — WSB says: MIXED (55% bullish) Claude says: DISAGREE — NBIS at $217 is below the Fib 23.6% retracement of $240.80 and below its 6-month high of $286.69; the chart structure is bearish consolidation, not accumulation — the mixed sentiment is warranted but the technically correct read is that this needs to reclaim $240 before bulls have a real case.

INTC — WSB says: BULLISH (80% bullish) Claude says: PARTIALLY AGREE — INTC at $109 has nearly tripled off its 6-month low of $41.19, which is a genuine turnaround narrative, and it’s approaching the Fib 23.6% retracement resistance at $117.40; the 80% bullish read is aggressive but the trend is genuinely up — just don’t chase above $117 without consolidation.

AMD — WSB says: BULLISH (80% bullish) Claude says: AGREE — AMD at $549 is approaching its 6-month high of $580.91, trading well above its 50-day SMA of $495, and the AI chip demand tailwind is real and validated by multiple data points this week; this is one of the cleaner bullish technical setups among WSB’s favorites — the 80% bullish read is justified.

SPCX — WSB says: BEARISH (30% bullish) Claude says: AGREE — SPCX at $155.68 is sitting below nearly every Fib retracement level from its 6-month high of $211.39, and it’s only marginally above its 50-day SMA of $134.69; with 4,989 upvotes on bearish posts, WSB has correctly identified this as a distribution phase — the bearish thesis is technically supported.

Earnings Scorecard

TCOM — REPORTED | Stock: +1.4% | EPS Actual: $5.16 Trip.com beat on both EPS and revenue with international OTA revenue jumping sharply, but the +1.4% reaction is underwhelming for what sounds like a solid print — the muted response likely reflects macro concerns about Chinese consumer spending and rate sensitivity in travel; this looks like a hold rather than a chase, but the thesis is intact if international travel demand data continues to improve.